Comparison · NCT00666276-cd1d96ac
Linezolid-over 65 vs Linezolid-less Than 65: Factors Considered to Affect the Safety of Linezolid - Age
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Linezolid-over 65 vs Linezolid-less Than 65: Factors Considered to Affect the Safety of Linezolid - Age. Trial comparisons, record NCT00666276-cd1d96ac. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00666276-cd1d96ac
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.177 | 0.151 | 0.208 | wilson | |
| Risk in group 2 | 0.145 | 0.109 | 0.191 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0319 | -0.0212 | 0.0793 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.22 | 0.881 | 1.69 | log | |
| Odds ratio, group 1 over group 2 | 1.27 | 0.862 | 1.86 | log | |
| Number needed to treat, for one more participant with the outcome on Linezolid-over 65 than on Linezolid-less Than 65 | 31.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Linezolid-over 65 | Participants with over 65 years old who have been treated with Linezolid. | 122 | 688 | OG000 |
| Group 2 | Linezolid-less Than 65 | Participants with less than 65 years old who have been treated with Linezolid. | 41 | 282 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Factors Considered to Affect the Safety of Linezolid - Age
- Description
- Number of participants with adverse drug reaction to determine whether over 65 or less than 65 is significant risk factor.
- Time frame
- 8 weeks
- Population
- Safety analysis population consists of the participants that satisfy the inclusion and exclusion conditions and in whom administration of this drug was confirmed.
Source ClinicalTrials.gov
Trial
- Title
- Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
- NCT number
- NCT00666276
- Phases
- Conditions
- Staphylococcal Infections
- Interventions
- linezolid (Zyvox)
- Lead sponsor
- Pfizer
- Results first posted
- 2012-07-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00666276?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00666276-cd1d96ac